Effect of escitalopram versus placebo on GRα messenger RNA expression in peripheral blood cells of healthy individuals with a family history of depression - a secondary outcome analysis from the randomized AGENDA trial

TY - JOUR

T1 - Effect of escitalopram versus placebo on GRα messenger RNA expression in peripheral blood cells of healthy individuals with a family history of depression - a secondary outcome analysis from the randomized AGENDA trial

AU - Knorr, Ulla

AU - Koefoed, Pernille

AU - Gluud, Christian

AU - Wetterslev, Jørn

AU - Winkel, Per

AU - Gether, Ulrik

AU - Vinberg, Maj

AU - Kessing, Lars V

PY - 2016/5/18

Y1 - 2016/5/18

N2 - Background Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed as first-line drugs for the treatment of depression. However, the mechanisms of action for SSRIs are unclear and besides neurotransmitter modulation may depend on modulation of the hypothalamic-pituitary-adrenal (HPA) system. The glucocorticoid receptor (GR) isoform plays an important role in the negative feedback regulation of the HPA axis and reduced GR messenger RNA (mRNA) expression has been shown in mood disorder patients and first-degree relatives compared to healthy individuals with no family history of psychiatric disorders. Aim Based on the AGENDA trial dataset, we analysed whether an intervention with SSRI versus placebo decreases the GR mRNA expression in peripheral blood cells in healthy first-degree relatives of patients with major depression. Methods The participants (N = 80) were randomly allocated to receive daily tablets of escitalopram 10 mg versus placebo for 4 weeks. GR mRNA expression levels in peripheral blood were measured using reverse transcription polymerase chain reaction. Results Four weeks of intervention with escitalopram decreased the relative change from baseline in the expression of GR mRNA compared with placebo (p = 0.002). Conclusion These findings from a randomized trial suggest that a 4-week escitalopram administration to healthy participants results in a decrease in GR mRNA expression levels in peripheral blood compared with inert placebo. The decrease in GR mRNA expression levels may reflect a decrease in the HPA axis activity.

AB - Background Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed as first-line drugs for the treatment of depression. However, the mechanisms of action for SSRIs are unclear and besides neurotransmitter modulation may depend on modulation of the hypothalamic-pituitary-adrenal (HPA) system. The glucocorticoid receptor (GR) isoform plays an important role in the negative feedback regulation of the HPA axis and reduced GR messenger RNA (mRNA) expression has been shown in mood disorder patients and first-degree relatives compared to healthy individuals with no family history of psychiatric disorders. Aim Based on the AGENDA trial dataset, we analysed whether an intervention with SSRI versus placebo decreases the GR mRNA expression in peripheral blood cells in healthy first-degree relatives of patients with major depression. Methods The participants (N = 80) were randomly allocated to receive daily tablets of escitalopram 10 mg versus placebo for 4 weeks. GR mRNA expression levels in peripheral blood were measured using reverse transcription polymerase chain reaction. Results Four weeks of intervention with escitalopram decreased the relative change from baseline in the expression of GR mRNA compared with placebo (p = 0.002). Conclusion These findings from a randomized trial suggest that a 4-week escitalopram administration to healthy participants results in a decrease in GR mRNA expression levels in peripheral blood compared with inert placebo. The decrease in GR mRNA expression levels may reflect a decrease in the HPA axis activity.

U2 - 10.3109/08039488.2015.1109138

DO - 10.3109/08039488.2015.1109138

M3 - Journal article

C2 - 26752119

SN - 0803-9488

VL - 70

SP - 297

EP - 302

JO - Nordic Journal of Psychiatry

JF - Nordic Journal of Psychiatry

IS - 4

ER -